Clinical Trials

2,900 enrolled

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

NCT03682289 2026-04-15

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

GastrointestinalGenitourinaryGynecologic

89 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologic

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT04633239 2026-04-13

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

42 enrolled

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT05554328 2026-04-13

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

165 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05887609 2026-04-13

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

53 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06915025 2026-04-13

OVATION-3

500 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07024784 2026-04-06

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

377 enrolled

Fallopian Tube Neoplasms, Neoplasms

NCT06580314 2026-03-24

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

880 enrolled

Ovarian Neoplasms

NCT07460180 2026-03-10

PROOV

Phase 1/2 Recruiting

55 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT07371104 2026-03-05

Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer

40 enrolled

Neoplasms, Ovarian Neoplasms

NCT06712472 2026-01-20

RAINBO-RED

554 enrolled

Endometrial Neoplasms

NCT06856499 2026-01-09

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

50 enrolled

Fallopian Tube Neoplasms

NCT06545942 2025-12-23

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

220 enrolled

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04644289 2025-10-03

WoO

60 enrolled

Carcinoma, Ovarian Epithelial

NCT05932862 2025-09-05

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

BreastGastrointestinalGenitourinaryGynecologic

429 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07069335 2025-07-16

A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer

24 enrolled

Ovarian Neoplasms

NCT06686030 2025-04-16

Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

150 enrolled

Platinum-sensitive Ovarian Cancer

NCT05200260 2025-02-10

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

220 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05255653 2024-11-29

RAINBO

Phase 2/3 Recruiting

1,615 enrolled

Endometrial Neoplasms

NCT06377267 2024-05-09

STROBE

100 enrolled

Ovarian Neoplasms

NCT05255471 2023-03-24

MITO 35B

200 enrolled